NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
OHSU Knight Cancer Institute
Novartis
Novartis
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
GlaxoSmithKline